European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemicals for next generation risk assessment

Descripción del proyecto

Desarrollo del futuro de la experimentación sin animales

Diversos productos que se utilizan en la vida cotidiana utilizan sustancias químicas que requieren pruebas para garantizar que no son perjudiciales. Se suelen utilizar animales para probar los efectos de estos productos químicos sobre distintas partes y órganos del cuerpo, por lo que se requiere un nuevo método de pruebas acorde a los principios modernos. El proyecto financiado con fondos europeos ONTOX tiene como objetivo proporcionar un método sin animales vanguardista para probar sustancias químicas. Lo conseguirá a través de un enfoque novedoso que predice los efectos de los productos químicos sobre el cuerpo mediante inteligencia artificial combinada con datos médicos multidisciplinares y experimentos. Este método podría ayudar a la adopción rápida de la experimentación sin animales, a la vez que establece la posición de liderazgo de Europa en la evaluación del riesgo de los productos químicos.

Objetivo

The vision of the ONTOX consortium is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next generation risk assessment. Specifically, ONTOX will deliver a generic strategy to create innovative new approach methodologies (NAMs) in order to predict systemic repeated dose toxicity effects that, upon combination with tailored exposure assessment, will enable human risk assessment. This strategy can be applied to any type of chemical and systemic repeated dose toxicity effect. However, for proof-of-concept purposes, focus will be put on 6 specific NAMs addressing adversities in the liver (steatosis and cholestasis), kidneys (tubular necrosis and crystallopathy) and developing brain (neural tube closure and cognitive function defects) induced by a variety of chemicals, including from the pharmaceutical, cosmetics, food and biocide sectors. The 6 NAMs will each consist of a computational system based on cutting-edge artificial intelligence (AI) and will be primarily fed by available biological/mechanistic, toxicological/epidemiological, physico-chemical and kinetic data. Data will be consecutively integrated in physiological maps, quantitative adverse outcome pathway networks and ontology frameworks. Data gaps, as identified by AI, will be filled by targeted state-of-the-art in vitro and in silico testing. The 6 NAMs will be evaluated and applied in collaboration with industrial and regulatory stakeholders in order to maximise end-user acceptance and regulatory confidence. This is anticipated to expedite implementation in risk assessment practice and to facilitate commercialisation. ONTOX will have a deep and long-lasting impact at many levels, in particular by consolidating Europe’s world-leading position regarding the development, exploitation, regulation and application of animal-free methods for human risk assessment of chemicals.

Convocatoria de propuestas

H2020-SC1-BHC-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SC1-2020-Single-Stage-RTD

Régimen de financiación

RIA - Research and Innovation action

Coordinador

VRIJE UNIVERSITEIT BRUSSEL
Aportación neta de la UEn
€ 2 491 262,50
Dirección
PLEINLAAN 2
1050 Bruxelles / Brussel
Bélgica

Ver en el mapa

Región
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 2 491 262,50

Participantes (18)